Eribulin has been found to improve survival in patients with metastatic or locally recurrent breast cancer who have received heavy chemotherapy before.

Treatment with Eribulin in this trial improved survival of patients by almost two and a half months. Side effects of the drug were also possible to treat.
Eribulin acts at a new site on the cancer cells and inhibits cell division. It has the advantages that it can be relatively easily administered, has a short infusion time and the patient need not be pretreated with any drugs to prevent an allergic reaction. Eribulin caused side effects like neutropenia (low WBC count), fatigue and peripheral neuropathy (problem with nerves that could cause symptoms like tingling, numbness and muscle weakness). Neutropenia was managed with reduction and/or delay in the dose and administration of granulocyte colony stimulating factor.
Based on this study, Eribulin has been approved in the USA for the treatment of metastatic breast cancer for those patients that have received at least two chemotherapeutic regimens. These regimens should include anticancer drugs from the anthracycline and taxane classes.
Source-Medindia